A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, Girald P. Miletello, Brendan D. Curti, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Sigrun Hallmeyer, Joseph I. Clark, Rene Gonzalez, John M. Richart, Joe Lutzky, Michael A. Morse, Ryan J. Sullivan, David F. McDermott

Open source

DOI: 10.1186/s40425-016-0155-8
Published: 2016-09-20
Container: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s40425-016-0155-8,
  title = {A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma},
  author = {Elizabeth I. Buchbinder and Anasuya Gunturi and Jessica Perritt and Janice Dutcher and Sandra Aung and Howard L. Kaufman and Marc S. Ernstoff and Girald P. Miletello and Brendan D. Curti and Gregory A. Daniels and Sapna P. Patel and John M. Kirkwood and Sigrun Hallmeyer and Joseph I. Clark and Rene Gonzalez and John M. Richart and Joe Lutzky and Michael A. Morse and Ryan J. Sullivan and David F. McDermott},
  year = {2016},
  journal = {Journal for ImmunoTherapy of Cancer},
  doi = {10.1186/s40425-016-0155-8},
  url = {https://doi.org/10.1186/s40425-016-0155-8}
}

RIS

TY  - JOUR
TI  - A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
AU  - Elizabeth I. Buchbinder
AU  - Anasuya Gunturi
AU  - Jessica Perritt
AU  - Janice Dutcher
AU  - Sandra Aung
AU  - Howard L. Kaufman
AU  - Marc S. Ernstoff
AU  - Girald P. Miletello
AU  - Brendan D. Curti
AU  - Gregory A. Daniels
AU  - Sapna P. Patel
AU  - John M. Kirkwood
AU  - Sigrun Hallmeyer
AU  - Joseph I. Clark
AU  - Rene Gonzalez
AU  - John M. Richart
AU  - Joe Lutzky
AU  - Michael A. Morse
AU  - Ryan J. Sullivan
AU  - David F. McDermott
PY  - 2016
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1186/s40425-016-0155-8
UR  - https://doi.org/10.1186/s40425-016-0155-8
ER  -

APA

Buchbinder, E. I., Gunturi, A., Perritt, J., Dutcher, J., Aung, S., Kaufman, H. L., Ernstoff, M. S., Miletello, G. P., Curti, B. D., Daniels, G. A., Patel, S. P., Kirkwood, J. M., Hallmeyer, S., Clark, J. I., Gonzalez, R., Richart, J. M., Lutzky, J., Morse, M. A., Sullivan, R. J., & McDermott, D. F. (2016). A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-016-0155-8

Source records

crossref · retrieved 2026-09-25T14:21:26.708Z